510(k) · Cleared
ClearedBTL-699
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
BTL Industries, Inc. · OBP Transcranial Magnetic Stimulator
Cleared on Aug 23, 2026 as substantially equivalent to K251119 (Tonica Elektronik A/S, 2025) and 4 other predicates after a 173-day review. Its family tree reaches back 13 generations to 2008.
- Decided
- Aug 23, 2026
- Review
- 173 days
- Class
- Class II
- Product code
- OBP
- Recalls
- None
- Predicates
- 5
Its longest line of descent runs back 13 generations to DEN070003 (2008). 30 ancestors in all. No later device cites it as a predicate yet.
- Root · 13 generations backDEN070003 Neurostar TMS SystemNeuronetics · 2008
- 9 generations between
- 3 generations backK230029 NeuroStar Advanced Therapy System (Version 3.7)Neuronetics · 2023
- 2 generations backK231926 NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 2024 · Recalled
- 1 generation backK251125 MagVenture TMS Therapy SystemTonica Elektronik A/S · 2025
- This deviceK260691 BTL-699BTL Industries, Inc. · 2026
Show all 13 generations
- Root · 13 generations backDEN070003 Neurostar TMS SystemNeuronetics · 2008
- 12 generations backK083538 Neurostar TMS Therapy System, Model 1.1Neuronetics · 2008 · Recalled
- 11 generations backK130233 Neurostar TMS Therapy SystemNeuronetics · 2013
- 10 generations backK133408 Neurostar TMS Therapy SystemNeuronetics · 2014
- 9 generations backK143531 Rapid Therapy SystemMagstim Company Limited · 2015 · Recalled
- 8 generations backK160309 Neurosoft TMSTeleemg, LLC · 2016
- 7 generations backK171967 MagVita TMS Therapy SystemTonica Elektronik A/S · 2017
- 6 generations backK173620 Mag Vita TMS Therapy System w/Theta Burst StimulationTonica Elektronik A/S · 2018
- 5 generations backK193006 MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS…Tonica Elektronik A/S · 2020
- 4 generations backK212289 NeuroStar Advanced Therapy for adjunctive treatment of OCD…Neuronetics, Inc. · 2022
- 3 generations backK230029 NeuroStar Advanced Therapy System (Version 3.7)Neuronetics · 2023
- 2 generations backK231926 NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 2024 · Recalled
- 1 generation backK251125 MagVenture TMS Therapy SystemTonica Elektronik A/S · 2025
- This deviceK260691 BTL-699BTL Industries, Inc. · 2026
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −13 | DEN070003 | Neurostar TMS System | Neuronetics | 2008 | — |
| −12 | K083538 | Neurostar TMS Therapy System, Model 1.1 | Neuronetics | 2008 | 1 |
| −11 | K130233 | Neurostar TMS Therapy System | Neuronetics | 2013 | — |
| −10 | K133408 | Neurostar TMS Therapy System | Neuronetics | 2014 | — |
| −9 | K143531 | Rapid Therapy System | Magstim Company Limited | 2015 | 3 |
| −8 | K160309 | Neurosoft TMS | Teleemg, LLC | 2016 | — |
| −7 | K171967 | MagVita TMS Therapy System | Tonica Elektronik A/S | 2017 | — |
| −6 | K173620 | Mag Vita TMS Therapy System w/Theta Burst Stimulation | Tonica Elektronik A/S | 2018 | — |
| −5 | K193006 | MagVenture TMS Therapy – for treatment of OCD, MagVenture TMS Therapy system | Tonica Elektronik A/S | 2020 | — |
| −4 | K212289 | NeuroStar Advanced Therapy for adjunctive treatment of OCD, NeuroStar Advanced… | Neuronetics, Inc. | 2022 | — |
| −3 | K230029 | NeuroStar Advanced Therapy System (Version 3.7) | Neuronetics | 2023 | — |
| −2 | K231926 | NeuroStar Advanced Therapy System (All previously cleared models) | Neuronetics, Inc. | 2024 | 1 |
| −1 | K251125 | MagVenture TMS Therapy System | Tonica Elektronik A/S | 2025 | — |
| 0 (this device) | K260691 | BTL-699 | BTL Industries, Inc. | 2026 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2013 | 1 | 0 |
| 2015 | 1 | 0 |
| 2016 | 2 | 0 |
| 2017 | 3 | 0 |
| 2018 | 2 | 0 |
| 2019 | 1 | 0 |
| 2020 | 1 | 0 |
| 2021 | 1 | 0 |
| 2022 | 2 | 0 |
| 2023 | 1 | 0 |
| 2024 | 1 | 0 |
| 2025 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in OBP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new OBP device
- #1 K251119 MagVenture TMS Therapy Systemscore 21.8 · 11 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (5)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K251119 | MagVenture TMS Therapy SystemSummary page 6…Number: K212723 510(k) Number: K230657 Original 510(k) Sponsor: BTL Original 510(k) Sponsor: BTL 510(k) Number: K251119 Industries, Inc. Industries, Inc. Original 510(k) Sponsor: Tonica Elektr… | 2025 |
| * | K212723 | BTL-995-rTMSSummary page 6…Secondary predicate device: MagVenture TMS Therapy BTL-995-rTMS BTL-99-OC System 510(k) Number: K212723 510(k) Number: K230657 Original 510(k) Sponsor: BTL Original 510(k) Spons… | 2022 |
| * | K230657 | BTL-99-OCSummary page 6…MagVenture TMS Therapy BTL-995-rTMS BTL-99-OC System 510(k) Number: K212723 510(k) Number: K230657 Original 510(k) Sponsor: BTL Original 510(k) Sponsor: BTL 510(k) Number: K251119… | 2024 |
| * | K233621 | NeuroStar Advanced Therapy System (Version 3.8)Summary page 6…es, Inc. Industries, Inc. Original 510(k) Sponsor: Tonica Elektronik A/S Third precicate device: NeuroStar Advanced Therapy System 510(k) Number: K233621 Original 510(k) Sponsor: Neuronetics, Inc. For treatment of adjunct Major Depressive Disorder in adolescent patients (age 15-21)… | 2023 |
| * | K251125 | MagVenture TMS Therapy SystemSummary page 6…s, Inc. For treatment of adjunct Major Depressive Disorder in adolescent patients (age 15-21). Primary predicate device: MagVenture TMS Therapy System 510(k) Number: K251125 Original 510(k) Sponsor: Tonica Elektronik A/S Product Description The BTL-699 is a non-invasive therapeutic device that gene… | 2025 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 18 years and passes through 6 companies; a new generation was cleared every 1.1 years on median.
- 4 of the 30 ancestors have a recall of any class.
- 2 other devices also cite its predicate K251119.
How does its category compare?
All OBP devicesOBP Transcranial Magnetic Stimulator: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.
FDA decisions per year · OBP
12in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · OBP
125in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · OBP
1in 2018
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · OBP
81in 2025
MAUDE reports naming product code OBP, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 2 | — | 0 | 0 |
| 2009 | 0 | — | 1 | 3 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 5 |
| 2012 | 0 | — | 0 | 3 |
| 2013 | 2 | — | 0 | 1 |
| 2014 | 1 | — | 0 | 0 |
| 2015 | 2 | — | 0 | 3 |
| 2016 | 3 | 101 | 0 | 6 |
| 2017 | 8 | 73 | 0 | 3 |
| 2018 | 4 | 144 | 1 | 6 |
| 2019 | 3 | 156 | 0 | 12 |
| 2020 | 1 | — | 0 | 12 |
| 2021 | 5 | 132 | 0 | 15 |
| 2022 | 6 | 168 | 0 | 59 |
| 2023 | 7 | 119 | 0 | 43 |
| 2024 | 5 | 266 | 0 | 50 |
| 2025 | 12 | 125 | 0 | 81 |
| 2026 | 8 | 176 | 1 | — |
What is it indicated for?
The BTL-699 is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
The BTL-699 is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
The BTL-699 is indicated as an adjunct for the treatment of Major Depressive Disorder in adolescent patients (age 15-21).
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K260691 · printed Nov 6, 2026
Cite this page
510(k) Report. “K260691: BTL-699.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K260691
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded Oct 30, 2026
- Summary read Oct 30, 2026 (extraction version 2d9447fa9ea4)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026